Zimmer Biomet Holdings, Inc.

NYSE:ZBH

Medical - Devices

Healthcare
$103.32 +1.00%

+$0.87 today

Market cap
$19.55B
Beta
0.47
P/E (TTM)
22.5
EPS (TTM)
$3.90
Dividend yield
1.09%
52W Low $79.12High $108.29

Volume 2.34M

Average 2.28M

ZBH EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Zimmer Biomet Holdings, Inc.NYSE: ZBH

EBITDA · Q2 FY2026 · quarter ended Jun 2026

EBITDA grows in line with its trailing trend

Q2 FY2026 EBITDA of $598.8M rose 4.0% year over year, ahead of the +2.7% change in trailing-twelve-month EBITDA. Sequentially, it fell 7.3% from the prior quarter. Over 3 fiscal years it compounded at +14.1% a year.

Context

  • EBITDA amounted to 26.9% of revenue in FY2025, down 2.4 pp from a year earlier.
  • EBITDA increased in 2 of the last 3 fiscal years.

What to watch

Whether EBITDA reaches the consensus estimate from 19 analysts of $3.27B (+47.4%) for the fiscal year ending Dec 2026, a step up from the -1.5% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$598.8M-7.3% QoQ
Last fiscal yearDec 2025
$2.22B-1.5% YoY
LTMJun 2026
$2.34B+2.7% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+4.0%+25.4%+21.4 pp
1 year-1.5%+47.4%+48.9 pp
3-year CAGR+14.1%+13.0%-1.0 pp
5-year CAGR+9.3%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
2.22B USD
Year-over-year change
-1.5%
4-year CAGR
+7.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How ZBH compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +2.7% is the 6th highest of 10, against a peer median of +9.8%.
  • EBITDA amounts to 27.5% of revenue for ZBH, versus a peer median of 21.7%.
ZBH Competitors
EBITDA for ZBH and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MDTMedtronic plcLTM Jul 2026$10.27B USD+9.8%+4.1%27.3%
SYKStryker CorporationLTM Jun 2026$6.69B USD+40.7%+16.3%25.9%
BSXBoston Scientific CorporationLTM Jun 2026$5.8B USD+23.2%+23.0%27.6%
GEHCGE HealthCare Technologies Inc.LTM Jun 2026$3.07B USD-19.7%+6.1%15.2%
PHGKoninklijke Philips N.V.LTM Jun 2026€3.05B EUR+62.1%+184.2%17.3%
ZBHZimmer Biomet Holdings, Inc.LTM Jun 2026$2.34B USD+2.7%+14.1%27.5%
EWEdwards Lifesciences CorporationLTM Jun 2026$1.58B USD-11.2%-9.6%24.3%
SNNSmith & Nephew plcFY2025$1.34B USD+0.1%+5.1%21.7%
ALGNAlign Technology, Inc.LTM Jun 2026$786.32M USD-2.2%+1.8%19.0%
OFIXOrthofix Medical Inc.LTM Mar 2026$94.51M USD+693.8%—11.5%
Peer median (excluding ZBH) —+9.8%+5.6%21.7%

Competitors are the stored peer set for ZBH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue6.83B6.94B7.39B7.68B8.23B
Cost of Revenue1.96B2.02B2.08B2.19B3.16B
Gross Profit4.87B4.92B5.31B5.49B5.07B
Gross Margin71.3%70.9%71.8%71.5%61.6%
Research & Development435.8M406M458.7M437.4M458.5M
Selling, General & Admin2.84B2.76B2.84B2.93B3.25B
Operating Expenses4.01B4.22B4.03B4.2B3.71B
Depreciation & Amortization937.7M926.4M951.7M996.3M1.09B
EBITDA1.65B1.49B2.22B2.25B2.22B
EBITDA Margin24.1%21.5%30.0%29.3%26.9%
Operating Income860.3M696.3M1.28B1.29B1.36B
Operating Margin12.6%10.0%17.3%16.7%16.5%
Interest Income00000
Interest Expense208.4M164.8M201.2M218M292.8M
Other Income / Expenses(361.3M)(292.8M)(210.4M)(249.1M)(531.4M)
Income Before Tax499M403.5M1.07B1.04B830.8M
Pre-Tax Margin7.3%5.8%14.4%13.5%10.1%
Income Tax Expense53.5M112.3M42.2M131.4M125.7M
Net Income401.6M231.4M1.02B903.8M705.2M
Net Margin5.9%3.3%13.8%11.8%8.6%
EPS (Basic)1.871.104.914.453.56
EPS (Diluted)1.851.104.884.433.55
Weighted Avg Shares214.86M209.6M208.7M203.1M198M
Weighted Avg Shares (Diluted)216.71M210.3M209.7M203.9M198.7M

Zimmer Biomet Holdings, Inc.

NYSE:ZBH

Intrinsic Alpha fair value

Locked

Current Price

$103.32

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.